Navigation Links
Hemostemix Announces US Patent Allowance
Date:6/5/2013

Kyriat Weizmann, Israel (PRWEB) June 05, 2013

Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a Notice of Allowance from the United States Patent and Trademark Office for a patent entitled “A Composition Comprising A Progenitor/Precursor Cell Population”.

The patent pertains to a population of cultured cells which meet certain criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence later this year.

This patent is part of a broad technology platform now protected by 38 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.

“The cell population which is the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “is an important pillar of our technology. This cell population is generated from a core population of cells we named Synergetic Cell Population (“SCP”), which is isolated from a simple blood collection. We believe the SCP not only has the potential to differentiate into blood vessels, but can also be transformed, through proprietary cell-culturing techniques, into other cell types, such as cardiomyocyte-like cells and neural cells.”

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group. On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) ("Technical") regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/USPTOallowance/prweb10777870.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Arteriocyte announces Launch of Compass Biomedical
5. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
6. Elsevier Announces its Collaboration with Kasetsart University, Thailand
7. Celsion Corporation Announces $9.83 Million Registered Direct Offering
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. 3SBio Inc. Announces Completion of Merger
10. AtheroNova Announces Shipment of Phase 1 Drug Product
11. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research or ... for more than half a century. Despite their essential roles in human health ... known that molecular tags developed for this purpose also tag other, more abundant, non-stem ...
(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica accounts ... and abiotic factors. During this educational webinar, participants will learn about the importance ... gain a better understanding of how genomics is important for coffee breeding improvement. ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... provide essential device-to-computer interconnect using USB or PCI Express, announced the release of ... SYZYGY is intended to satisfy the need for a compact, low cost, low ...
(Date:8/11/2017)... , ... August 11, 2017 , ... A staple in ... this month that will incorporate important key elements including a new digital marketing strategy ... that has supported them, Bill Miller has partnered with the South Texas Blood & ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):